Sign Out
Timolol ophthalmic solution has not been studied in human pregnancy. However, timolol may cross the placenta with the potential to cause adverse effects of beta-blockade e.g., bradycardia in foetus and neonate. Timolol ophthalmic solution should therefore not be used in pregnancy unless the potential benefit to the pregnant women justifies the potential risk to the foetus.
Timolol ophthalmic solution may be systemically absorbed and excreted in the breast milk, with the potential to cause adverse effects related to beta-blockade in the infant. Treatment during breastfeeding is therefore not recommended unless the potential benefit to the nursing mother justifies the potential risk both to the infant and to the mother.
Continue with Google